Skip to content

Blood levels of proteins (which protects the brain) in alcohol dependent patients, patient with alcohol withdrawal symptoms and in patients who stopped drinking.

Profile of neuroimmune regulatory proteins and associated glycoproteins in alcohol dependence, withdrawal and abstinence.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2019/01/017271
Enrollment
156
Registered
2019-01-25
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F102- Alcohol dependence

Interventions

Sponsors

Applied to DSTSERB
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Male inpatient in the age group of 20 to 50 years, diagnosed with alcohol use disorder according to DSM-5 and admitted for detoxification treatment as Shree Dharmasthala Manjunatheshwara De-addiction and Research center, Ujire. 2) Patient with an AUDIT score above 8.

Exclusion criteria

Exclusion criteria: 1) They are on any prior disulfiram therapy or deaddiction program. 2) They are taking any other medication or on hormonal therapy. 3) If they have any known physical or psychiatric illnesses or any chronic disorder such as diabetes mellitus, tuberculosis, epilepsy, cerebrovascular accident, and seizures. 4) Less than 8 points in an AUDIT.

Design outcomes

Primary

MeasureTime frame
Blood levels of neuroimmune regulatory proteins in alcohol dependence, withdrawal and in abstinenceTimepoint: At the end of four years

Secondary

MeasureTime frame
To evaluate the severity of craving, withdrawal symptoms and alcohol dependence in the above patients using standardized questionnaireTimepoint: At the end of four years

Countries

India

Contacts

Public ContactABHISHEK CHATURVEDI

Melaka Manipal Medical College

guruprasad.rao@manipal.edu9448109225

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026